Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: USA Family Office Invests in Global Therapeutics, Devices, and Diagnostics, with Strong Interest in Discovery to Pre-Clinical Technologies

18 Jul

A family office based in the USA invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies. The firm will generally lead investments and invests globally with no geographic restrictions.

The firm is agnostic across life science sectors, including therapeutics, devices and tools, but will not consider healthcare IT or digital health technologies. The firm focuses on discovery, early stage preclinical and clinical-stage opportunities, though may be open to commercial-stage or adjacent discovery/ development technologies.

The firm is seeking companies with founders who have a clear vision and desire to build a durable business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Large China Biologics Company Seeks Novel Antibody Product Candidates for Potential In-Licensing and Strategic Partnership

18 Jul

A large biologics company headquartered in China with additional operations in USA and Asia, focuses on the development and commercialization of antibody-based therapeutics using advanced technologies. The company has a special focus on biosimilars and biobetters (mAbs and recombinant proteins) for malignant tumors (including solid tumor, lymphoma, etc.) and auto-immune diseases. Currently, the company’s pipeline covers over 8 biosimilars and 10 novel antibody products in pre-clinical and clinical development.

In addition to seeking out-licensing opportunities and strategic partnerships, the company is also seeking to in-license novel antibody product candidates in oncology that has synergies with the company’s current portfolio.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of USA Health System Invests in Medical Devices & Digital Health Companies with Strong Strategic Alignment

18 Jul

A new venture capital firm established in early 2019 by a large network of hospitals, clinics, and home care services in the USA does direct, strategic investment in early-stage companies (with approximately half of this allocation dedicated to follow-on investments). The firm’s initial investments are usually in the range of $1-3M. The firm is geography agnostic and will consider all technologies across the globe.

The firm’s investments focuses on these 4 verticals: digital health, medical devices, healthcare technology systems, and healthcare services. The firm will not invest in biopharmaceuticals or in vitro diagnostics, though they may consider life science tools. In terms of medical devices, the firm prefers to invest in products who have achieved FDA approval, though the firm may consider and is open to speaking with earlier stage companies with strong fit. The firm expects technologies to have a strong alignment with the hospital network, and these technologies need to be useable and easily integrated with the health system. Practically, the firm expects to have a contract (or direct line of sight to a contract) at the time of investment. Some areas of particular interest include mental and behavioral health, postpartum care, interoperability among devices and health records, cognitive support for millennials, use of voice to diagnose and monitor health conditions, etc. Overall, the firm will take high interest in technologies that help deliver care outside of the hospital.

While the firm has no specific team requirements, the firm does like to see entrepreneurs and management teams with a strong tie to the product or market. To date, the firm has only done follow-on investments as part of a syndicate, but will be open to acting as lead investor in future opportunities, most likely starting from 2020 and beyond.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: